聯合疫苗市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球聯合疫苗市場價值為 126 億美元，預計將以 10.2% 的複合年成長率成長，到 2034 年達到 323 億美元。

這一激增的動力源於人們日益重視透過積極主動的醫療保健來預防疾病。聯合疫苗正獲得強勁發展勢頭，因為它們透過將針對多種疾病的保護合併為一劑，簡化了免疫接種流程。這不僅最大限度地減少了所需的注射次數，還提高了依從性，簡化了物流，並提高了疫苗接種覆蓋率，尤其是在醫療資源匱乏的地區。隨著醫療保健系統尋求更有效率的解決方案，這些疫苗在支持高通量免疫接種工作、減少就診次數和減輕營運負擔方面發揮著至關重要的作用。其可擴展性使其在國家和全球疫苗接種策略中都至關重要，進一步凸顯了其在公共衛生領域日益成長的重要性。

結合疫苗市場在2024年創造了52億美元的收入，這得益於其強大的安全性和可靠的性能，尤其是在嬰幼兒群體中。這類疫苗利用蛋白質連接抗原來激發更強的免疫反應，被廣泛應用於針對多醣包衣病原體引起的疾病的免疫接種計劃。結合疫苗被納入採購管道，顯著增強了其在已開發經濟體和新興經濟體的影響力。

2024年，控股部門的市佔率為56.4%；兒科部門仍是聯合疫苗消費的主要驅動力。高出生率和多價免疫接種方案的廣泛採用確保了兒科疫苗需求保持強勁。在政策授權和國際支持的支持下，這些疫苗通常在生命早期階段接種，有助於減輕疾病負擔和減少就診次數，同時最佳化全民免疫工作。

2024年，北美聯合疫苗市場佔據40.2%的市佔率。該地區受益於先進的醫療基礎設施、積極的公共衛生舉措以及強大的疫苗研發實力。對聯合疫苗創新的投資，加上日益提升的認知度和普及度，繼續鞏固了其在該地區的優勢地位。國家免疫指南和兒童聯合疫苗的定期接種進一步提升了美國和加拿大市場的滲透率。

領先的聯合疫苗市場參與者包括默克、輝瑞、科興、葛蘭素史克、印度血清研究所、賽諾菲、武田、CSL、第一三共、巴拉特生物技術、阿斯利康、帕那西生物技術、明治、MTPC、北京民海生物技術、田邊三菱、Emergent BioSolutions和沃森生物技術製藥。在聯合疫苗市場競爭的公司正大力投資，透過先進的研發來擴大其產品組合，推出針對新發和再發疾病的新型多價製劑。與政府機構、衛生組織和採購機構建立策略合作夥伴關係有助於獲得大規模合約並改善全球分銷。監管協調和快速核准也是獲得市場吸引力的關鍵。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 日益重視預防性醫療保健
    • 對便利性和合規性的需求不斷成長
    • 政府措施和支持措施
    • 擴大兒童免疫接種計劃
    • 增強臨床意識和免疫指南
  • 產業陷阱與挑戰
    • 嚴格的法規核准流程
    • 開發和生產成本高
    • 冷鍊和儲存挑戰
  • 市場機會
    • 加強疫苗分發的公私夥伴關係
    • 擴大成人疫苗接種計劃
• 成長潛力分析
• 監管格局
• 管道分析
• 技術格局
• 投資和融資格局
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 公司矩陣分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按技術分類，2021 - 2034 年

• 主要趨勢
• 共軛
• 減毒活疫苗
• 去活化
• 重組
• 類毒素
• 其他技術

第6章：市場估計與預測：按年齡層，2021 - 2034 年

• 主要趨勢
• 兒科
• 成人

第7章：市場估計與預測：按疾病，2021 - 2034

• 主要趨勢
• 白喉、破傷風和百日咳 (DTP)
• 小兒麻痺
• 肝炎
• 流感
• 人類乳突病毒（HPV）
• 水痘
• 麻疹、腮腺炎和德國麻疹 (MMR)
• 其他疾病

第8章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 醫院
  • 民眾
  • 私人的
• 專科診所
• 其他最終用途

第9章：市場估計與預測：按地區，2021 - 2034

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• AstraZeneca
• Beijing Minhai Biological Technology
• Bharat Biotech
• CSL
• Daiichi Sankyo
• Emergent BioSolutions
• GlaxoSmithKline (GSK)
• Meiji
• Merck
• Mitsubishi Tanabe Pharma (MTPC)
• Panacea Biotec
• Pfizer
• Sanofi
• Serum Institute of India
• Sinovac
• Takeda
• Walvax Biotechnology

The Global Combination Vaccines Market was valued at USD 12.6 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 32.3 billion by 2034.

This surge is fueled by increasing emphasis on disease prevention through proactive healthcare. Combination vaccines are gaining strong momentum as they streamline immunization by merging protection against multiple diseases into one dose. This not only minimizes the number of injections required but also enhances compliance, simplifies logistics, and improves vaccination coverage-particularly in underserved regions. As healthcare systems seek more efficient solutions, these vaccines are proving vital in supporting high-throughput immunization efforts with fewer clinic visits and reduced operational burden. Their scalable nature makes them crucial in both national and global vaccination strategies, reinforcing their growing relevance in public health.

The conjugate vaccine segment generated USD 5.2 billion in 2024, backed by its strong safety profile and reliable performance, especially among infants and young children. These vaccines, which use a protein-linked antigen to provoke stronger immune responses, are widely incorporated into immunization programs targeting diseases caused by polysaccharide-coated pathogens. Their inclusion in procurement pipelines has significantly strengthened their presence in both developed and emerging economies.

The holding segment held a 56.4% share in 2024; the pediatric segment remains the primary driver of combination vaccine consumption. High birth rates and widespread adoption of multivalent immunization schedules have ensured that pediatric demand remains resilient. Backed by policy mandates and international support, these vaccines are routinely administered in early life stages, helping reduce disease burden and medical visits while optimizing immunization efforts across populations.

North America Combination Vaccines Market held 40.2% share in 2024. The region benefits from advanced healthcare infrastructure, proactive public health initiatives, and robust vaccine R&D. Investment in combination vaccine innovation, coupled with heightened awareness and uptake, continues to support regional dominance. National immunization guidelines and regular administration of combined vaccines for children further boost market penetration across the United States and Canada.

Leading Combination Vaccines Market participants include Merck, Pfizer, Sinovac, GSK, Serum Institute of India, Sanofi, Takeda, CSL, Daiichi Sankyo, Bharat Biotech, AstraZeneca, Panacea Biotec, Meiji, MTPC, Beijing Minhai Biological Technology, Mitsubishi Tanabe Pharma, Emergent BioSolutions, and Walvax Biotechnology. Companies competing in the combination vaccines market are investing heavily in expanding their product portfolios through advanced R&D to introduce new multivalent formulations that target emerging and re-emerging diseases. Strategic partnerships with government agencies, health organizations, and procurement bodies are helping secure large-scale contracts and improve global distribution. Regulatory alignment and fast-track approvals are also central to gaining market traction.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Technology trends
  • 2.2.3 Age group trends
  • 2.2.4 Disease trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising emphasis on preventive healthcare
    • 3.2.1.2 Growing demand for convenience & compliance
    • 3.2.1.3 Government initiatives and supportive measures
    • 3.2.1.4 Expanding pediatric immunization programs
    • 3.2.1.5 Enhanced clinical awareness and immunization guidelines
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory approval processes
    • 3.2.2.2 High development and production costs
    • 3.2.2.3 Cold chain & storage challenges
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing public-private partnerships for vaccine distribution
    • 3.2.3.2 Expanding adult vaccination programs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Pipeline analysis
• 3.6 Technology landscape
• 3.7 Investment and funding landscape
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Company matrix analysis
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Conjugate
• 5.3 Live attenuated
• 5.4 Inactivated
• 5.5 Recombinant
• 5.6 Toxoid
• 5.7 Other technologies

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Pediatric
• 6.3 Adult

Chapter 7 Market Estimates and Forecast, By Disease, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Diphtheria, Tetanus, and Pertussis (DTP)
• 7.3 Polio
• 7.4 Hepatitis
• 7.5 Influenza
• 7.6 Human Papillomavirus (HPV)
• 7.7 Varicella
• 7.8 Measles, Mumps, and Rubella (MMR)
• 7.9 Other diseases

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
  • 8.2.1 Public
  • 8.2.2 Private
• 8.3 Specialty clinics
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AstraZeneca
• 10.2 Beijing Minhai Biological Technology
• 10.3 Bharat Biotech
• 10.4 CSL
• 10.5 Daiichi Sankyo
• 10.6 Emergent BioSolutions
• 10.7 GlaxoSmithKline (GSK)
• 10.8 Meiji
• 10.9 Merck
• 10.10 Mitsubishi Tanabe Pharma (MTPC)
• 10.11 Panacea Biotec
• 10.12 Pfizer
• 10.13 Sanofi
• 10.14 Serum Institute of India
• 10.15 Sinovac
• 10.16 Takeda
• 10.17 Walvax Biotechnology